Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection.
Haas
Michael J
MJ
Department of Medicine, University of Florida College of Medicine, Jacksonville, Florida 32209, USA. michael.haas@jax.ufl.edu
Mooradian
Arshag D
AD
D000818:Animals; D016632:Apolipoprotein A-I / Q000096:biosynthesis* / Q000235:genetics; D001692:Biological Transport; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism*; D015195:Drug Design; D006801:Humans; D008075:Lipoproteins, HDL / Q000096:biosynthesis*; D011401:Promoter Regions, Genetic / Q000187:drug effects; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists / Q000037:antagonists & inhibitors; D014158:Transcription, Genetic / Q000187:drug effects
D016632:Apolipoprotein A-I; D002316:Cardiotonic Agents; D008075:Lipoproteins, HDL; D018160:Receptors, Cytoplasmic and Nuclear; D002784:Cholesterol